Celldex Therapeutics Inc.


Market Cap$2.71B

Compare Celldex Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Celldex Therapeutics Inc.Celldex Therapeutics Inc.-18.70%-17%--
marketMarket Avg54.31.27%32%-1.3
HealthcareHealthcare Avg39.11.36%17%7.21.3

Current Fair Value

111.6% downside

Overvalued by 111.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.71 Billion
Enterprise Value$1.88 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-2.82
Outstanding Shares65,910,548
Avg 30 Day Volume593,981


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-18.68
Price to Sales-
Price to Book Ratio3.33
Enterprise Value to Revenue310.02
Enterprise Value to EBIT-12.53
Enterprise Value to Net Income-13
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

ESG Score

No data

About Celldex Therapeutics Inc.

CEO: Anthony Marucci

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...